B&O: Back with a Bang?

Danish high-end consumer electronics maker Bang & Olufsen has been struggling ever since the Great Recession. It is not surprising that the stock is down from its highs in 2006–2007. However, I was indeed a bit surprised that it’s down by a staggering 98%! Even since a temporary recovery attempt that culminated in 2018, the stock has fallen by more than 90%! Over the last twelve months, though, shares are up by 46%. Management has ambitious plans to bring the struggling brand back on track. Could this be now a good entry point?

Continue reading

Is Insmed a Promising Biotech Blockbuster? + new research report

Insmed, a biotech company with one approved drug and a very promising pipeline, in the last 13 months saw its stock going up by a factor of no less than 4x – plus 300%! There were two key events each propelling the stock decisively higher. Both were updates on ongoing clinical trials only. I am saying deliberately “only”, because it is not even a given that biotechs surge so much after drugs get approved by the FDA, yet, here it happened twice following just updates to clinical trials. The reason: Insmed’s assets are very promising with each potentially achieving blockbuster status (> 1 bn. USD is sales, both potentially multi-billions). Is it now time to jump onto this precious opportunity? My Premium PLUS members will soon receive my latest stock idea with a much more attractive setup.

Continue reading

The case of e.l.f. Beauty — chic story meets a glamorous valuation

The comparatively young company e.l.f. Beauty is famous among younger generations thanks to low-price, high-value and cruelty-free cosmetics. Its stunning rise, disrupting the industry with bold innovation, has glossed its stock with a remarkable run, reflecting glamorous growth and consistent market share gains for years. After its peak, the stock fell by three quarters and has more than doubled again since then. After the latest earnings, shares surged by more than 20% as a big acquisition was announced. Is this a beautiful compounder to have an eye on?

Continue reading

WD-40: an overlooked portfolio lubricant?

Last Sunday, I finally went after an annoying task that had been waiting for me for too long: to remove sticky and really ugly glue from an entire big window frame. My first attempts failed miserably and I had left it untouched for some time. But that stuff needed to be finally done. After some research, I found the solution: WD-40, the home workers best friend. While in full swing, I remembered that WD-40 is also a publicly listed company! The stock has practically always been extremely expensive, but I haven’t covered it for years. Time for an update to answer the question whether this is a smooth slide or a rusty bet.

Continue reading

Third time’s the charm? Is Capri finally a buy?

I already discussed the stock of Capri Holdings twice last year, prior to and after the failed takeover attempt by Tapestry. Capri’s stock fell even below my lower target of 20 USD from initially 35 USD. Now, sitting around 15 USD and having announced the sale of troubled Versace, many things have changed, requiring a reassessment of the case. If the sale goes through, the balance sheet flips from net debt to net cash at current figures. Also, loss-making Versace will stop to be a burden for the group. Is the third time now finally the charm?

Continue reading

Is Fannie Mae really a safe multi-bagger?

Readers who like spicier ideas by now might have heard about ongoing discussions of a potential release of two (in)famous US mortgage companies from conservatorship, i.e. a possible privatization. Yes indeed, state-owned (or partly-owned) enterprises aren’t just a thing of perceived socialist or communist countries. At the latest after none other than hedge fund billionaire Bill Ackman pitched his investment case aggressively on Twitter, stocks of Fannie Mae and Freddie Mac have made big waves. According to Ackman, there’s still a substantial upside of 5x left (after already being up by 5x since November). Is this THE no-brainer opportunity for 2025?

Continue reading

Halozyme Therapeutics – an overlooked bargain? + new stock idea

Feeling uncomfortable with everybody’s darling stocks, my motivation was and still is to find stock ideas with what I call “an own life”. With that I am looking for companies with internal triggers or catalysts which can influence shares positively (almost) regardless of what broader markets do. While I do not believe (for now) in a hefty stock market crash which pushes down all equities, I cannot rule out a nosebleed correction in the tech sector. In search of uncorrelated stock ideas, I spent some time on the Pharma / biotech sector. Halozyme Therapeutics is a seemingly lowly-valued stock. My Premium PLUS members have already received my latest potential-multi-bagger stock idea in an exclusive research report to kick off the year 2025.

Continue reading

Stocks of Dollar Stores – now finally a buy?

This Weekly is an update taking a second look at North American “dollar store” operators Dollar General and Dollarama. After almost exactly to the day two years ago, I featured both names in an analysis concluding that I have sympathies for the businesses as such, but not for their stocks. Something quite interesting has happened since: one stock totally cratered, the other advanced by another 75%. The development could not have been more different! What do both have in store now?

Continue reading

Drill Baby, drill + new research report “Trump Trade 2.0”

One of the expectations for the second term of president-elect Donald Trump is that “dirty” energy will see a huge revival due to pushing back the strict ESG policies of the current administration. Less wind and solar and back to more oil, gas and coal, maybe with nuclear mixed in. However, despite the perception being that Trump is good for oil and gas producers, the above would be exactly the opposite as more supply means lower energy prices. Will we see aggressive drilling and lower energy prices or shall we prepare for something entirely different? All my members receive my latest stock idea, my second “Trump Trade” which should be a big beneficiary either way.

Continue reading

InPost – polish highflier transforms Europe’s parcel delivery market

Delivering parcels to so called parcel machines instead of to the door of the receiver is a major growth story. Coming with benefits for all parties, this win-win concept has not only transformed many big (former) state-owned postal businesses by infusing some new growth into them. It has also created a Polish company that has specialized exactly on this business without operating capital-intensive logistics or legacy mail. It is rolling up many European markets full-steam. The last coup: a takeover in the UK, the continent’s biggest e-commerce market. Is InPost’s stock a must-own?

Continue reading